Latest News
Everpure's Q1 Report: Analysts Optimistic Amid Rising Supply Costs
Everpure Inc. is set to report its first fiscal Q1 2027 results on May 27, with analysts forecasting a 19% upside, though rising input costs for semiconductors pose a challenge.
Moderna Shares Surge on Hantavirus Vaccine Interest After Andes Virus Outbreak on Cruise Ship
Moderna shares rose nearly 12% after an Andes virus outbreak on a cruise ship drew attention to its early-stage hantavirus vaccine, though WHO rates public risk low.
Intel Shares Hit Record on Apple Foundry Deal Report; BofA Warns Rally Overdone
Intel shares jumped 14% to a record $124.92 after reports of a preliminary chipmaking deal with Apple. BofA raised its price target but maintained an Underperform rating, saying the potential deal is already priced in.
Sandisk Hits Record High as AI Storage Demand Drives $245B Market Cap
Sandisk shares hit an all-time high of $1,562.34, pushing its market cap to $245 billion as AI data-center demand fuels a 251% revenue surge.
Hims & Hers Earnings: Weight-Loss Strategy in Focus as GLP-1 Shift Unfolds
Hims & Hers Health reports Q1 earnings Monday after close, with Wall Street expecting ~$617M revenue. The key focus: how its weight-loss business performs after shifting from compounded GLP-1 drugs to FDA-approved options from Novo Nordisk.
Everspin Technologies Surges on $40M Defense MRAM Deal
Everspin Technologies shares rose 25% to $26.99 after announcing a $40 million defense subcontract for domestic MRAM production, with Q1 revenue reaching $14.9 million.
Micron Surges on AI Memory Demand as Chip Rally Intensifies
Micron Technology shares surged 15.5% to $746.81 on Friday, fueled by soaring demand for AI memory chips. Q2 revenue reached $23.86 billion, and Q3 guidance of $33.5 billion underscores the strategic importance of memory in AI.
Pfizer's COVID Patent Woes Persist as Investors Eye Growth Beyond Vaccines
A Delaware federal judge dismissed Acuitas Therapeutics' attempt to clear Pfizer's Comirnaty vaccine from GSK patent claims, leaving the patent dispute unresolved. Pfizer shares fell 1.42% to $25.68.
Trade Desk Stock Slumps as Q2 Revenue Forecast Misses Wall Street Targets
The Trade Desk shares fell sharply after the company's Q2 revenue guidance of $750M missed analyst expectations of $771M, prompting multiple downgrades.